Mon.Sep 16, 2024

article thumbnail

Intercept's liver med Ocaliva takes heat at FDA expert meeting, as hopes for full approval dim

Fierce Pharma

Following a meeting with the FDA’s Gastrointestinal Drug Advisory Committee Friday, the future of Intercept’s rare liver disease drug Ocaliva is under serious threat. | Looking to assess whether Ocaliva met its postmarketing requirements after a 2016 accelerated approval in the autoimmune disease primary biliary cholangitis, an FDA council of outside experts nearly unanimously rejected Intercept’s hopes for a full approval.

FDA 240
article thumbnail

*EVENT* The Silent Edge: October 9 in NYC

Authentic Influence Group

The Silent Edge: How Body Language and Communication Skills Shape Leadership Success October 9, 2024 | 8:00 AM | NYC Free Event | Limited to 30 Seats Enjoy a Breakfast Bagel | Take in the NYC Skyline | Master Leadership Through Body Language Harness the power of what’s not being said. Join Shelly O’Donovan to master body language that transforms your leadership presence, influences decisions, and builds stronger teams.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lilly's immunology unit scores another FDA nod with eczema treatment Ebglyss

Fierce Pharma

Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U.S. | Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U.S. regulator has signed off on IL-13 inhibitor Ebglyss, or lebrikizumab, to treat atopic dermatitis.

FDA 229
article thumbnail

New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds

MedCity News

Eli Lilly drug Ebglyss is now FDA-approved for atopic dermatitis, an inflammatory skin disorder also known as eczema. The biologic drug came from Lilly’s $1.1 billion acquisition of Dermira in 2020. The post New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds appeared first on MedCity News.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

ESMO: Despite survival miss, Exelixis presses on with FDA prostate cancer bid as Ipsen scraps EU plan

Fierce Pharma

The same set of clinical data on Cabometyx and Tecentriq in prostate cancer has led to two distinct regulatory plans between Exelixis and its partner Ipsen. | The same set of clinical data on Cabometyx and Tecentriq in prostate cancer has led to two distinct regulatory plans between Exelixis and its partner Ipsen.

FDA 173
article thumbnail

We’re Overcomplicating Healthcare AI — Here’s How We Achieve Impact Beyond The Hype

MedCity News

It’s important that we focus attention on the areas where AI is already having a significant impact. These are the practical applications that will allow the best and brightest researchers to focus on science rather than data munging. The post We’re Overcomplicating Healthcare AI — Here’s How We Achieve Impact Beyond The Hype appeared first on MedCity News.

More Trending

article thumbnail

Where is Pediatric Innovation Making an Impact?

MedCity News

Pediatric innovation in mental health is the theme of the INVEST Digital Health Pitch Perfect contest at Pegasus Park in Dallas on September 18. The post Where is Pediatric Innovation Making an Impact? appeared first on MedCity News.

109
109
article thumbnail

After the Lykos debacle, what’s next for psychedelic therapies?

Pharmaceutical Technology

While Lykos Therapeutics’ MDMA therapy was rejected by the FDA, psychedelic therapy advocates remain optimistic about the sector.

FDA 119
article thumbnail

Providence Health Plan, American Heart Association Launch Cardiovascular Health Initiative

MedCity News

Providence Health Plan and the American Heart Association will create blood pressure programs in 20 community organizations and clinics over three years. The post Providence Health Plan, American Heart Association Launch Cardiovascular Health Initiative appeared first on MedCity News.

110
110
article thumbnail

Support app for young cancer patients launches in UK

pharmaphorum

Rates of cancer among people aged 24 and below are rising fast, but health systems are often not catering well enough to the specific needs of this age group.A new partnership has been set up between the Ella Dawson Foundation, a UK-based charity for young people with cancer, and digital cancer care company Careology to try to tackle that deficit and improve their treatment and wellbeing.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

A Crystal Ball for Cancer Survivors

MedCity News

This test can be thought of as a crystal ball for cancer survivors and research has found it can predict with near certainty whether a patient’s cancer will recur. So why aren’t more patients getting the test? The post A Crystal Ball for Cancer Survivors appeared first on MedCity News.

article thumbnail

ESMO: Pfizer drug helps cancer patients gain weight

pharmaphorum

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia in a phase 2 trial presented at ESMO

Patients 102
article thumbnail

FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech

Pharmaceutical Technology

Roche has secured approval from the US Food and Drug Administration for Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology.

article thumbnail

AbbVie faulted for misleading ad featuring Serena Williams

pharmaphorum

FDA raps AbbVie for 'misleading' ad for migraine drug Ubrelvy featuring tennis star Serena Williams

FDA 116
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Lilly’s EBGLYSS gains FDA approval for patients aged 12 and older

Pharmaceutical Technology

Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12.

FDA 98
article thumbnail

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

pharmaphorum

AstraZeneca reveals 'practice changing' data for Imfinzi as peri-operative therapy for bladder cancer, but will the FDA accept the study?

FDA 102
article thumbnail

Boehringer seeks approval for lung fibrosis drug following Phase III win

Pharmaceutical Technology

The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.

98
article thumbnail

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

pharmaphorum

J&J plans phase 3 trials for Rybrevant in colorectal cancer, after reporting positive results for the METxEGFR bispecific antibody at ESMO

87
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Not Your Average Bra: How Bloomer Tech’s Wearable Is Addressing Heart Disease in Women

MedCity News

MIT spinout Bloomer Tech is developing a wearable electrocardiogram device designed to look and feel like a bra. The post Not Your Average Bra: How Bloomer Tech’s Wearable Is Addressing Heart Disease in Women appeared first on MedCity News.

63
article thumbnail

ESMO: Incyte's PD-1 treads new ground in anal cancer

pharmaphorum

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programme back on track.Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category but picked up its first approval in the rare tumour Merkel cell carcinoma last year.

FDA 78
article thumbnail

WHO adds first mpox vaccine to prequalification list

PharmaTimes

The decision is expected to facilitate timely access to Bavarian Nordic’s Imvanex

97
article thumbnail

Agility in action: 5 ways to fast-track your clinical trial

PharmaVoice

Five ways to beat study timeline pressures and get medicines to patients faster.

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis

PharmExec

Results from the ADvocate 1, ADvocate 2, and ADhere clinical trials found that patients treated with Ebglyss 38% of patients with moderate-to-severe atopic dermatitis achieved clear or almost-clear skin after 16 weeks of treatment.

FDA 52
article thumbnail

Biopharma prepares to pivot from China as Biosecure Act advances

PharmaVoice

After the House of Representatives passed the Biosecure Act last week, U.S. biotechs could be forced to cut ties with five Chinese contract partners.

article thumbnail

Delivery and Disruption: Navigating a Changing Care Terrain

PharmExec

The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.

article thumbnail

The hunt for game-changers against the deadliest form of brain cancer

PharmaVoice

Treatments for glioblastoma have fallen short in the face of difficult challenges, but the pipeline is full of renewed attempts.

59
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Outsourcing’s Evolution in the Pharma Industry

PharmExec

Amid shifting operating dynamics in recent years, demands for external expertise have fluctuated—leaving those arrangements that mix innovation and agility likely to win out in pharma decision-making.

Pharma 52
article thumbnail

Pioneering ePRO and eCOA innovations for next-generation clinical trials

Pharmaceutical Technology

As clinical trials become more complex, the need for innovative solutions to capture patient data accurately and efficiently is more critical than ever.

article thumbnail

Telehealth & Its Role in Providing Access to Weight Loss Drugs

PharmExec

In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, share their predictions for the future of telehealth and its role in providing access to essential medications like weight loss drugs

Medical 52
article thumbnail

Minimizing risks in pharmaceutical supply chains: what you need to know

Pharmaceutical Technology

Having a specialty logistics partner that can act as lookout for pharmaceutical manufacturers is critical amid supply chain uncertainty.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A